Liege (Belgium) - December 23, 2008, 2:00 PM CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that it has received the following shareholder notifications as a consequence of the capital increase announced on December 16 and completed on December 18, 2008:
• A number of funds managed by AGF Private Equity, part of the Allianz AG insurance group, became a new shareholder on December 18, 2008 through the subscription of newly issued common shares in the framework of the capital increase and as a result hold together 6.04% of the outstanding shares of the company;
• Stichting Pensioenfonds ABP subscribed to newly issued common shares in the framework of the capital increase completed on December 18, 2008 which, together with the shares it already held in the company, brought its shareholding to 4.38%;
• The number of shares held by Technowal SA has not changed, but as a result of the capital increase completed on December 18, 2008, its participation diluted to 2.85% (i.e. less than 3%) of the outstanding shares of the company;
• The number of shares held by the funds managed by Edmond de Rothschild Investment Partners has not changed, but as a result of the capital increase completed on December 18, 2008, its participation diluted to 9.60% (i.e. less than 10%) of the outstanding shares of the company;
• A number of funds managed by ING Investment Management informed the company that they own together 8.17% of the outstanding shares of the company. The number of shares held by ING Belgium NV/SA itself has not changed.
For further details on the transparency notifications received by the company, reference is made to our website www.oncomethylome.com.
About OncoMethylome Sciences
OncoMethylome Sciences SA (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company’s tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient’s response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
OncoMethylome Sciences SA boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, and Millipore Corporation’s BioScience Division. OncoMethylome Sciences’ products are based on methylation technology invented by Johns Hopkins University (USA).
Established in January 2003, OncoMethylome Sciences SA has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
